

Contents

Part I. Innate Immunity in Autoimmune Diseases

1. Innate Immunity in Experimental Autoimmune Myocarditis

Ziya Kaya and Noel R. Rose

| | |
|---|----|
| 1. Introduction | 1 |
| 2. Experimental Models of Myocarditis in Mice | 2 |
| 2.1. Coxsackievirus B3 (CB3)-Induced Autoimmune Myocarditis | 2 |
| 2.2. Cardiac Myosin-Induced Autoimmune Myocarditis | 2 |
| 2.3. Peptide-Induced Myocarditis | 3 |
| 3. Susceptibility to Myocarditis | 3 |
| 4. Mouse Genotype | 4 |
| 5. Innate Immune System and Myocarditis | 5 |
| 5.1. Complement and Myocarditis | 6 |
| 5.2. NK Cells and Myocarditis | 8 |
| 5.3. Cytokines and Myocarditis | 8 |
| 5.4. Chemokines and Myocarditis | 10 |
| 6. Conclusions | 11 |
| Acknowledgments | 11 |
| References | 12 |

2. Toll-like Receptor 9 and Autoimmunity

Paul N. Moynagh

| | |
|--|----|
| 1. Introduction | 17 |
| 2. TLRs as Receptors for Pathogen-Associated Molecules | 17 |
| 3. TLR9 and the Immunostimulatory Effects of Bacterial DNA | 18 |
| 4. TLR9 and Intracellular signaling | 18 |
| 5. CpG Sequences in Self-DNA Trigger Autoantibody Production | 20 |
| 6. TLR9 as a Target for Regulating RF Production | 21 |
| 7. Concluding Remarks | 22 |
| Acknowledgments | 22 |
| References | 22 |

3. C-Reactive Protein as a Regulator of Autoimmune Disease

Terry W. Du Clos and Carolyn Mold

| | |
|--|----|
| 1. Introduction | 27 |
| 2. Structural Features of CRP | 27 |
| 3. CRP as an Acute-Phase Reactant | 28 |
| 4. CRP Interaction with Nuclear Antigens | 29 |
| 5. CRP, SAP, and Nuclear Antigen Clearance | 30 |
| 6. CRP Genetics and Autoimmunity | 31 |
| 7. CRP Levels in Human SLE | 31 |
| 8. CRP in Animal Models of Autoimmunity | 32 |
| 9. CRP in Immune Complex Nephritis | 33 |
| 10. CRP in Inflammation | 34 |
| 11. Identification of Fc γ R as CRP Receptors | 34 |
| 12. Role of Fc γ R in CRP Effects on Inflammation | 35 |
| 13. Essential Role of IL-10 in Anti-inflammatory Activities of CRP | 37 |
| 14. Current Perspective on CRP in Autoimmune Disease | 37 |
| References | 38 |

4. NKT Cells and Autoimmune Type 1 Diabetes

Shabbir Hussain, Dalam Ly, Melany Wagner, and Terry L. Delovitch

| | |
|--|----|
| 1. Introduction | 43 |
| 2. Type 1 Diabetes | 44 |
| 3. NKT Cells | 44 |
| 4. Role of iNKT Cells in the Pathogenesis of Type 1 Diabetes | 45 |
| 4.1. iNKT Cell Deficiency and T1D | 45 |
| 4.2. iNKT Cell Activation Induces Protection against Type 1 Diabetes | 47 |
| 5. Future Directions | 49 |
| Acknowledgments | 50 |
| References | 50 |

Part II. Genetics of Autoimmune Diseases

5. The Genetics of Human Autoimmune Diseases

Marta E. Alarcón-Riquelme

| | |
|---|----|
| 1. Introduction | 55 |
| 2. Analysis of the Genetics of Complex Diseases | 56 |
| 2.1. Linkage Analysis | 56 |
| 2.2. Association Analysis | 57 |
| 2.3. Combining Linkage and Association | 58 |
| 3. Genetic Analysis in Autoimmunity | 58 |
| 3.1. Genome Scans and Linkage Analysis in Autoimmune Diseases | 58 |
| 3.2. Autoimmune Diabetes (T1D) | 58 |
| 3.3. Multiple Sclerosis (MS) | 59 |

| | |
|---|----|
| 3.4. Rheumatoid Arthritis (RA) | 60 |
| 3.5. Crohn’s Disease (CD) and Ulcerative Colitis (UC) | 61 |
| 3.6. Systemic Lupus Erythematosus (SLE) | 62 |
| 3.7. Genes Shared between Autoimmune Diseases | 63 |
| References | 64 |

6. Failure to Maintain T Cell DNA Methylation and Chromatin Structure Contributes to Human Lupus

Donna Ray and Bruce Richardson

| | |
|--|----|
| 1. Introduction | 69 |
| 2. DNA Methylation, Chromatin Structure, and Gene Expression | 70 |
| 3. DNA Methylation and Drug-Induced Lupus | 73 |
| 3.1. DNA Methylation and Autoimmunity | 73 |
| 3.2. DNA Methylation and Drug-Induced Lupus | 75 |
| 3.3. T Cell Genes Affected by DNA Methylation Inhibitors | 76 |
| 4. Aberrant T cell DNA Methylation, Gene Expression, and Cellular Function in Idiopathic Lupus | 77 |
| 4.1. DNA Methylation | 77 |
| 4.2. Gene Expression and Cellular Function | 78 |
| 5. Conclusions | 80 |
| References | 81 |

7. Complement Components C4A and C4B in Human Lupus

Yan Yang, Erwin K. Chung, Karl Lhotta, Yee Ling Wu, Gloria C. Higgins, Robert M. Rennebohm, Lee A. Hebert, Daniel J. Birmingham, Brad H. Rovin, and C. Yung Yu

| | |
|---|----|
| 1. Introduction | 85 |
| 2. Diversities of Complement Components C4A and C4B in Human Populations | 86 |
| 2.1. Dichotomy in Gene Sizes, Polygenes, and RCCX Module Variants | 86 |
| 2.2. Diversity of Human C4A and C4B Proteins | 87 |
| 2.3. Genetic Determinants of C4 Plasma/Serum Protein Levels | 89 |
| 3. Complete Deficiencies of C4A and C4B in SLE and Immune-Complex Diseases | 90 |
| 3.1. Molecular Basis of Complete C4 Deficiency | 90 |
| 3.2. Impairment of Immune Response in C4-Deficient Patients | 91 |
| 4. Deficiencies of C4A or C4B in Human SLE | 92 |
| 4.1. Low Complement Activity and C4 Protein Concentrations in SLE | 92 |
| 4.2. Homozygous or “partial” Deficiency of C4A in SLE across multiple ethnic groups | 92 |
| 4.3. Deficiency of C4B in SLE Patients from Spanish, Mexican, and Australian Aborigines | 93 |
| 4.4. Partial Deficiencies versus Polygenic Variations of C4A and C4B | 94 |
| 5. Concluding Remarks and Perspectives | 94 |
| Acknowledgments | 95 |
| References | 96 |

8. Non-MHC Genetic Polymorphisms with Functional Importance for Human Myasthenia Gravis

Ann Kari Lefvert

| | |
|---|-----|
| 1. Introduction | 101 |
| 2. Pro- and Anti-inflammatory Cytokines in MG | 102 |
| 2.1. Association of MG to the High Secretory Alleles of TNF- α | 102 |
| 2.2. Functional Implications of the Association with the TNF- α -308 A2 Allele | 103 |
| 2.3. Association of MG to the high secretory Allele of IL-1 β | 103 |
| 2.4. Functional Implications of the Association with the IL-1 β TaqI RFLP A2 Allele | 104 |
| 2.5. Lack of Associations of MG to Genetic Variants of IL-4 and IL-6 | 105 |
| 2.6. IL-10 Is Associated to MG with High Autoantibody Levels | 105 |
| 3. The β 2-Adrenergic Receptor in MG | 105 |
| 4. The T Cell Receptor Cofactor CTLA-4 in MG | 106 |
| 4.1. Association to MG with Thymoma and Increased Activation of the Immune System | 106 |
| 4.2. Functional Correlates to the Genetic Variants of <i>Ctla-4</i> | 107 |
| 4.3. The C/T SNP at -318 | 108 |
| 4.4. The A/G SNP in CDS1 | 108 |
| 4.5. Promoter SNPs -1772 (C/T) and -1661 (A/G) | 108 |
| 4.6. CTLA-4 and Thymomas | 109 |
| 4.7. <i>Ctla-4</i> (AT) n Is Associated to ADCC | 109 |
| 5. Conclusions | 109 |
| Acknowledgments | 110 |
| References | 110 |

Part III. Triggers of the Autoimmune Attack

9. Rheumatic Heart Disease: Molecular Basis of Autoimmune Reactions Leading to Valvular Lesions

Luiza Guilherme, Kellen Faé, and Jorge Kalil

| | |
|--|-----|
| 1. Introduction | 115 |
| 2. The Etiopathogenic Agent: <i>Streptococcus Pyogenes</i> | 116 |
| 3. Genetic Susceptibility | 116 |
| 4. Molecular Mimicry and RF/RHD | 118 |
| 4.1. The Humoral Immune Response | 119 |
| 4.2. The Cellular Immune Response | 119 |
| 4.3. Humoral and Cellular Immune Responses Interface in RF/RHD | 121 |
| 4.4. T Cell Receptor (TCR) Usage | 121 |
| 5. Cytokines | 122 |
| 6. Animal Models | 122 |
| 7. Conclusions | 123 |
| References | 123 |

10. Autoimmunity against Desmogleins in Pemphigus Vulgaris

Christian Veldman and Michael Hertl

| | |
|--|-----|
| 1. Introduction | 127 |
| 2. Clinical Phenotype of Pemphigus Vulgaris | 128 |
| 3. Epidemiology of Pemphigus and Association with HLA Class II Alleles | 128 |
| 4. Pathogenesis of Pemphigus | 128 |
| 5. Autoantibody Reactivity against Desmogleins | 129 |
| 6. Autoreactive T Lymphocytes in Pemphigus | 132 |
| 7. Regulatory T Lymphocytes in Pemphigus | 134 |
| 8. Passive Animal Models of Pemphigus Vulgaris | 135 |
| 9. Active Animal Model of Pemphigus Vulgaris | 135 |
| 10. Conclusions | 135 |
| References | 136 |

11. The Molecular Basis of Celiac Disease

Liesbeth Spaenij-Dekking and Frits Koning

| | |
|---|-----|
| 1. Introduction | 141 |
| 2. T Cell Recognition of Gluten Peptides | 142 |
| 3. The Specificity of tTG Is Linked to Gluten Toxicity | 145 |
| 4. Additional T cell Stimulatory Peptides in Barley, Rye, and Oats | 145 |
| 5. The HLA Gene Dose Effect Is Linked to the Level of Gluten Presentation | 146 |
| 6. Generation of Safer Foods for Patients | 147 |
| 7. A Hypothesis for Disease Development | 147 |
| 8. Future Research and Perspectives | 148 |
| Acknowledgments | 149 |
| References | 149 |

12. Intrathymic Expression of Neuromuscular Acetylcholine Receptors and the Immunopathogenesis of Myasthenia Gravis

Arnold I. Levinson, Yi Zheng, Glen Gaulton, and Decheng Song

| | |
|---|-----|
| 1. Introduction | 151 |
| 2. Evidence Supporting the Role of the Thymus in MG Pathogenesis | 152 |
| 3. Expression of Neuromuscular AChRs by Thymic Cells | 153 |
| 4. The Thymus and Central Immune Tolerance | 157 |
| 5. The Thymus and T Cell Trafficking | 157 |
| 6. Development of an Experimental Model to Examine Peripheral T Cell Entry and Activation in the Thymus | 158 |
| 7. Conclusions | 160 |
| Acknowledgments | 160 |
| References | 161 |

Part IV. Targets of the Autoimmune Attack

13. Autoantibodies and Nephritis: Different Roads May Lead to Rome

Paola Migliorini, Consuelo Anzilotti, Laura Caponi, and Federico Pratesi

| | |
|---|-----|
| 1. Introduction | 165 |
| 2. Acute Poststreptococcal Glomerulonephritis | 167 |
| 3. Goodpasture's Syndrome | 169 |
| 4. Lupus Nephritis | 170 |
| 5. Other Nephritogenic Autoantibodies | 174 |
| 6. Conclusions | 175 |
| References | 176 |

14. Estrogen, Interferon-Gamma, and Lupus

S. Ansar Ahmed and Ebru Karpuzoglu-Sahin

| | |
|---|-----|
| 1. Introduction | 181 |
| 2. Estrogen and Lupus: Human and Animal Studies | 182 |
| 3. Mechanisms of Estrogen Effects on the Immune System | 185 |
| 3.1. Estrogen Exerts Its Biological Effects on Cells by Both Estrogen Receptor-Dependent and -Independent Mechanisms | 185 |
| 3.2. Estrogen Alterations of B cells | 189 |
| 3.3. Estrogen Effects on Cytokines | 189 |
| 4. IFN γ in SLE and Other Autoimmune Diseases | 190 |
| 5. Conclusions | 191 |
| Acknowledgments | 192 |
| References | 193 |

15. Extent of Regulatory T Cell Influence on Major Histocompatibility Complex Class II Gene Control of Susceptibility in Murine Autoimmune Thyroiditis

Yi-chi M. Kong, Gerald P. Morris, and Chella S. David

| | |
|--|-----|
| 1. Introduction | 197 |
| 2. Major Histocompatibility Complex (MHC) Class II Gene Control of Susceptibility | 198 |
| 3. Establishment of CD4 ⁺ T Cells as Mediators of Induced Resistance | 199 |
| 3.1. Protection from EAT Induction by Elevating Circulatory Thyroglobulin Level | 199 |
| 3.2. CD4 ⁺ Regulatory T Cells as Mediators of Induced Resistance | 200 |
| 3.3. Effect of Cytokines on CD4 ⁺ Regulatory T Cell Induction and Function | 200 |
| 4. CD25 Expression on CD4 ⁺ Regulatory T Cells in Induced Resistance | 201 |
| 4.1. Abrogation of Established Tolerance by CD4 ⁺ CD25 ⁺ T Cell Depletion | 201 |

| | |
|---|-----|
| 4.2. Interference with CD4 ⁺ CD25 ⁺ Regulatory T Cell Function by Cross-Linking TNFR Family Molecules | 203 |
| 5. Naturally Existing CD4 ⁺ CD25 ⁺ T Cells as Peripheral Barrier to Autoimmune Thyroiditis | 204 |
| 6. T Cell Regulation and MHC Restriction | 204 |
| 7. Conclusion | 206 |
| Acknowledgment | 206 |
| References | 206 |

16. The Role of Autoimmunity in Multiple Sclerosis

Monika Bradl and Hans Lassmann

| | |
|---|-----|
| 1. Introduction | 209 |
| 2. The “Autoimmune Hypothesis” of MS | 210 |
| 3. The Multiple Facets of Multiple Sclerosis | 210 |
| 3.1. The Clinical Spectrum of MS | 210 |
| 3.2. The Pathological Spectrum of MS | 211 |
| 3.3. Evidence for T Cell–Mediated Autoimmunity | 212 |
| 3.4. Evidence for B Cell– or Antibody-Mediated Autoimmunity | 215 |
| 3.5. Evidence for Autoimmunity from Immunotherapies of MS | 216 |
| 4. The Triggers for Autoimmune Reactions in MS Patients | 216 |
| 4.1. Autoimmune Reactions Caused by a Defect in Immune Regulation | 217 |
| 4.2. Autoimmune Reactions Caused by Infections | 218 |
| 5. Protective Autoimmunity | 220 |
| 6. What Remains of the “Autoimmune Hypothesis” of MS? | 220 |
| References | 221 |

Part V. Immune Receptor Signaling Pathways

17. Crippled B Lymphocyte Signaling Checkpoints in Systemic Autoimmunity

Moncef Zouali

| | |
|--|-----|
| 1. Introduction | 227 |
| 2. B Lymphocytes Participate in Both Innate and Adaptive Immunity | 228 |
| 3. The Critical Role of B Cells in Autoimmunity | 229 |
| 4. B Cell Receptor–Mediated Signaling Checkpoints | 230 |
| 5. Critical Regulators of B Cell Receptor Signaling | 231 |
| 6. Negative Regulators of B Cell Receptor–Mediated Signal Transduction | 234 |
| 7. Disrupted B Cell Signaling Pathways in Human Autoimmunity | 237 |
| 8. Conclusions | 239 |
| References | 239 |

18. Disrupted T Cell Receptor Signaling Pathways in Systemic Autoimmunity

Ana M. Blasini and Martín A. Rodríguez

| | |
|---|-----|
| 1. Introduction | 245 |
| 2. Signaling Pathways in T Cells | 246 |
| 3. T Cell Signaling Abnormalities in Systemic Autoimmune Disease | 250 |
| 3.1. Signaling Abnormalities in Antigen-Presenting Cells and Autoimmune Disease | 250 |
| 3.2. Signaling Abnormalities in T Cells and Autoimmune Disease | 252 |
| 4. Conclusions | 255 |
| Acknowledgments | 257 |
| References | 257 |

19. Immune Cell Signaling and Gene Transcription in Human Systemic Lupus Erythematosus

Christina G. Katsiari and George C. Tsokos

| | |
|---|-----|
| 1. Introduction | 263 |
| 2. Altered Pattern of Tyrosine Phosphorylation and Calcium Responses | 264 |
| 3. TCR ζ Chain Deficiency | 265 |
| 3.1. Impaired TCR ζ Chain Gene Transcription | 266 |
| 3.2. Impaired Translation and Posttranscription Events | 266 |
| 3.3. Impaired Posttranslational Functions | 267 |
| 3.4. Oxidative Stress | 267 |
| 3.5. Role of IFN γ | 268 |
| 4. Mechanisms of Increased TCR/CD3-Mediated $[Ca^{2+}]_i$ Response in SLE T Cells | 268 |
| 4.1. FcR γ Chain Substitutes for Defective ζ Chain | 268 |
| 4.2. Altered Composition and Dynamics of Lipid Rafts | 269 |
| 5. Protein Kinase A (PKA) Function | 271 |
| 6. Regulation of Transcription Determines Interleukin 2 Deficiency in SLE T Cells | 272 |
| 7. Conclusions | 274 |
| References | 275 |

20. Accumulation of Self-Antigens in Systemic Lupus Erythematosus

Koji Yasutomo

| | |
|---|-----|
| 1. Introduction | 279 |
| 2. T Cell in Human Lupus | 280 |
| 3. Antigen Clearance and Autoimmunity | 281 |
| 3.1. DNASE1-Deficient Patients: Gene Mutation and Clinical Features | 281 |
| 3.2. DNASE1-Deficient Patients: Laboratory Findings | 282 |
| 3.3. DNASE1-Deficient Patients: Effect on Autoreactivity | 282 |
| 4. Defective Clearance of Self-Antigens in SLE | 282 |
| 4.1. Evidence from Knockout Mice | 282 |

| | |
|---|-----|
| 4.2. Mechanisms of Accumulation of Self-Antigens in SLE | 284 |
| 4.3. Clearance of Self-Antigens as a Therapeutic Strategy | 286 |
| References | 286 |

Part VI. Immunointervention Strategies

21. B Lymphocyte Depletion Therapy in Autoimmune Disorders: Chasing Trojan Horses

Jonathan C. W. Edwards, Geraldine Cambridge, and Maria J. Leandro

| | |
|---|-----|
| 1. Introduction | 291 |
| 2. Human Autoimmunity: An Abnormality of B Cell Function | 291 |
| 2.1. A Brief History of Investigation of B and T Cell Autoreactivity in Human Autoantibody-Associated Diseases | 292 |
| 2.2. Generation of Autoreactive T Cells | 293 |
| 2.3. Autoantibodies as Effector Molecules | 294 |
| 2.4. Autoantibodies as Trojan Horse Immunomodulators | 294 |
| 3. Clinical Significance of the Trojan Horse Concept | 297 |
| 3.1. Effector Mechanisms in RA | 298 |
| 3.2. Logistics of B Cell Depletion | 299 |
| 3.3. Anti-CD20 Therapeutic Agents | 299 |
| 3.4. Rituximab | 300 |
| 3.5. Efficacy | 301 |
| 3.6. Failure of Seronegative Disease to Respond | 302 |
| 3.7. Adverse Events Associated with BLyD | 302 |
| 3.8. Repeated Cycles of B Cell Depletion | 303 |
| 4. Do Data from BLyD Support the Trojan Horse Concept? | 303 |
| 4.1. Autoantibody Levels Fall Selectively Compared with Antimicrobial and Total Immunoglobulin Levels | 303 |
| 4.2. Total Immunoglobulin Levels May Fall after Repeat Cycles | 304 |
| 4.3. Clinical Response Follows Serological Response, not B Cell Numbers .. | 305 |
| 4.4. The Kinetics of Relapse Follow Autoantibody Rises Rather than B Cell Return | 305 |
| 4.5. Why Are There Two Patterns of Relapse? | 306 |
| 5. Conclusions | 306 |
| References | 309 |

22. B lymphocyte Stimulator (BLyS) and Autoimmune Rheumatic Diseases

William Stohl

| | |
|---------------------------------|-----|
| 1. Introduction | 313 |
| 2. BLyS and Its Receptors | 313 |
| 2.1. General Biology | 313 |

| | |
|---|-----|
| 2.2. <i>In Vivo</i> Deficiency of BLYS or Its Receptors | 315 |
| 2.3. Supranormal Levels of BLYS <i>In Vivo</i> | 316 |
| 2.4. APRIL and Its Relevance to BLYS | 318 |
| 3. BLYS Antagonism as a Therapeutic Modality | 319 |
| 3.1. Mouse Models | 319 |
| 3.2. The Human Experience | 320 |
| 3.3. Which Patients Are Candidates for BLYS Antagonist Therapy? | 321 |
| 3.4. Concluding Comments | 322 |
| References | 322 |

23. Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments

Pierre Miossec

| | |
|---|-----|
| 1. Introduction | 329 |
| 2. TNF α and Its Receptors | 330 |
| 3. Mode of Action of the Specific TNF α Inhibitors | 331 |
| 4. The Local and Systematic Effects of TNF α Inhibition | 332 |
| 5. Understanding the Side Effects of TNF α Inhibitors | 335 |
| 6. Other Cytokine Inhibitors | 336 |
| 7. Other Cytokines as Treatment Targets | 337 |
| 8. Targeting One or More than One Cytokine | 337 |
| 9. Understanding the Heterogeneity of the Response to TNF α Inhibitors | 338 |
| 10. Autoimmune Manifestations with Cytokine Administration | 338 |
| 11. Conclusions | 341 |
| References | 341 |

24. Hematopoietic Stem Cell Transplantation for the Treatment of Severe Autoimmune Diseases

Alan Tyndall and Paul Hasler

| | |
|---|-----|
| 1. Introduction | 347 |
| 2. Autoimmune Disease Mechanisms | 348 |
| 3. Coincidental AD in Patients Receiving HSCT for Another Indication | 349 |
| 4. Animal Models | 350 |
| 5. Treatment of Human Autoimmune Disease with Hematopoietic Stem Cell Transplantation | 351 |
| 6. Systemic Sclerosis (SSc) | 353 |
| 7. Rheumatoid Arthritis | 353 |
| 8. Juvenile Idiopathic Arthritis | 354 |
| 9. Systemic Lupus Erythematosus | 354 |
| 10. Prospective Randomized Controlled Clinical Trials | 355 |
| 11. Open Issues | 356 |
| 11.1. Allogeneic HSCT | 356 |
| 11.2. Immune Reconstitution | 357 |
| 11.3. Ablative Therapy without HSCT | 358 |
| 12. Conclusions | 359 |
| References | 359 |

25. Molecular Mimicry in Autoimmune Uveitis: From Pathogenesis to Therapy

Gerhild Wildner, Maria Diedrichs-Moehring, and Stephan R. Thureau

| | |
|--|-----|
| 1. Introduction | 365 |
| 2. Retinal Autoantigens and Mimicry Peptides | 366 |
| 3. HLA Peptide B27PD in EAU | 367 |
| 4. Pathogenic and Tolerogenic Epitopes of the Retinal Peptide PDSA _g and Its Mimotope B27PD | 368 |
| 5. Antigenic Mimicry of Retinal Autoantigen and Environmental Antigens | 370 |
| 6. Treatment of Uveitis Patients with Oral Peptide B27PD | 372 |
| References | 374 |

26. Molecular Pathogenesis of the Antiphospholipid Syndrome: Toward Novel Therapeutic Targets

Silvia S. Pierangeli, Mariano Vega-Ostertag, Azzudin E. Gharavi, and E. Nigel Harris

| | |
|---|-----|
| 1. Introduction | 377 |
| 2. Antiphospholipid Antibodies and Platelets | 378 |
| 2.1. Effects of aPL on Platelets <i>In Vitro</i> and <i>In Vivo</i> | 378 |
| 2.2. Hydroxychloroquine in aPL-mediated thrombosis | 379 |
| 2.3. Intracellular Events in aPL-Mediated Platelet Activation | 380 |
| 3. Antiphospholipid Antibodies and Endothelial Cells | 381 |
| 3.1. Effects of aPL on Endothelial Cells | 381 |
| 3.2. The Statins and Antiphospholipid Antibodies | 385 |
| 3.3. Activation of the Complement Cascade and Antiphospholipid Antibodies | 385 |
| 4. Conclusions | 386 |
| Acknowledgement | 387 |
| References | 388 |

27. A Novel Approach to the Prevention of Atherosclerosis

Sun-Ah Kang and Marc Monestier

| | |
|--|-----|
| 1. Introduction | 393 |
| 2. Atherosclerosis | 393 |
| 2.1. Lesion Initiation | 394 |
| 2.2. Fatty Streak Formation | 395 |
| 2.3. Fibrous Plaques | 395 |
| 2.4. Plaque Rupture and Thrombosis | 396 |
| 3. Immune Cells in Atherosclerosis | 396 |
| 4. Cellular Immunity in Atherosclerosis | 397 |
| 5. Humoral Immunity in Atherosclerosis | 400 |
| 6. Vaccination or Immunoglobulin Administration in Atherosclerosis | 401 |
| 7. Conclusions | 402 |
| References | 403 |

28. Antigen-Specific Regulation of Autoimmunity*Amy E. Juedes and Matthias G. von Herrath*

| | |
|---|-----|
| 1. Introduction | 407 |
| 2. Antigen-Specific Therapy | 408 |
| 3. Antigen-Induced Regulatory T cells | 408 |
| 4. Factors Involved in Treg Induction | 410 |
| 4.1. Mechanisms of Protection | 411 |
| 4.2. Application to Human Disease | 412 |
| 5. Conclusions | 414 |
| References | 414 |
| Index | 419 |